Our analysis of TCGA data showed that subsets of both breast and hematological cancer patients (the diseases of ongoing trials) also overexpress TOP2B, most strikingly in some leukemias. The gene discussed is TOP2B; the disease is hematopoietic and lymphoid cell neoplasm.